To register, please go to:
With falling R&D productivity, increasing regulatory scrutiny, and patent expirations, big pharma realized the need to look beyond their internal R&D for innovation. One strategy is to partner with academia in discovering novel targets and further developing these early-stage assets into clinical phases. With continued federal budget cuts, the success rate in securing NIH grants is very low, putting financial pressures on academic researchers to look for alternative funding resources.
Despite increasing needs for external R&D collaboration for both academia and pharma, partnering remains challenging especially around confidentiality, publishing, and intellectual property rights and ownership. What is the best approach to manage these issues and bridge the gap between academic research and clinical development?
We will examine three models for academia - pharma alliances; the Pfizer CTI, GSK DPac, and Sanofi iAward Program. Our panelists are scientists and alliance representatives involved in the Pfizer CTI, GSK DPac and Sonofi iAward programs. They will share their experiences and perspectives including:
- Research program funding and selection process
- IP rights and ownership
- Termination of research program
- Success stories – Novel Medicines
- Brian Bates, PhD, Director of Biology, Pfizer Center for Therapeutic Innovation
- Amita Joshi, PhD, Director, R&D Alliance Management, Sanofi
- Weining Lu, MD, Associate Professor of Medicine, Department of Medicine, Boston University Medical Center
- Debra Peattie, PhD, MBA, Director & Entrepreneur-in-Residence, Alternative Discovery and Development, Discovery Partnerships with Academia at GSK
- Wanni Davis, PhD, MBA, Alliance Director, Technology Ventures Office, Beth Israel Deaconess Medical Center